Abstract Library

#3953 Olaparib use in a patient diagnosed with BRCA2 mutated adrenocortical carcinoma: A case report

Introduction: Adrenocortical carcinoma (ACC) is a highly lethal endocrine malignancy with an estimated annual incidence of 1.5–2 cases per million. Only a small percentage of ACC cases are associated with hereditary cancer syndromes while, equally only a few cases, have been reported with BRCA mutation. Targeted therapy of ACC with germline mutations is an area of research which renders the treatment approach challenging.

Conference:

Presenting Author:

Authors: Kontana E, Tikas I, Boudina M, Chrysoulidou A, Andreadou A,

Keywords: adrenocortical carcinoma, brca2 mutation, olaparib,

#3849 Is patient's BMI representative of their body composition in neuroendocrine tumors?

Introduction: Up to 60% of patients with neuroendocrine tumors (NETs) are malnourished. This negatively impacts survival, length of hospital stay, risk of complications, treatment response, fatigue and quality of life. Malnutrition is typically defined by body mass index (BMI) or weight loss, which provides no information on body composition. Research in other cancers has shown sarcopenia is more significant than BMI. Information is lacking on the influence of anthropometric parameters in NETs.

Conference:

Presenting Author: Bradley E

Authors: Bradley E, Shah T,

Keywords: neuroendocrine, body composition, handgrip strength, mid arm muscle circumference,

#3552 Fatigue and quality of life in patients with neuroendocrine neoplasia

Introduction: Neuroendocrine Neoplasms (NEN) are rare tumors and health related quality of life (HRQoL) may be modulated by the disease and the accompanying carcinoid syndrome seen especially in small intestinal NENs. Further, cancer related fatigue is one of the most common side effects of cancer and its treatments and may persist for years after treatment completion.

Conference:

Presenting Author: Hummelshøj N

Authors: Hummelshøj N, Grønbæk H, Bager P, Tabaksblat E, Dam G,

Keywords: Neuroendocrine, HRQoL, Fatigue, Patient reported outcome, Carcinoid syndrome,

#3451 Peptide Receptor Radionuclide Therapy (PRRT) and impact on quality of life in patients with neuroendocrine neoplasms: An international multi-centre study

Introduction: Neuroendocrine neoplasms (NENs) affect health-related quality of life (HRQOL) due to tumor burden, hormone-secretory symptoms, and treatment-related side effects.

Conference:

Presenting Author: Kong G

Authors: Kong G, Corsini N, Hogg A, Mercurio J, Bailey D,

Keywords: PRRT, HRQOL, Neuroendocrine neoplasm, Multi-centre study, QLQ-C30,

#3278 Simultaneously diagnosis of neuroendocrine neoplasm of unknown primary and breast cancer

Introduction: NeuroEndocrine Neoplasms (NENs) are considered rare neoplasms and can be developed in all organs.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Tsoukalas N

Authors: Tsoukalas N, Binas I, Kyriakopoulos G, Tassi V, Theodoroulea K,

Keywords: neuroendocrine neoplasm, intestinal, gastric, unknown primary, somatostatin analogues,